Aarti Drugs Limited has announced its 41st Annual General Meeting (AGM) will be held virtually on Saturday, September 26, 2026, at 11:00 a.m. IST. The meeting’s agenda includes the consideration and adoption of the standalone and consolidated financial statements for the financial year ended March 31, 2026, along with the auditor’s and directors’ reports. Key resolutions also cover the re-appointment of directors and approval of remuneration, including profit-related commissions for non-executive directors.
Aarti Drugs Announces 41st Annual General Meeting
Aarti Drugs Limited will convene its 41st Annual General Meeting (AGM) on Saturday, September 26, 2026, at 11:00 a.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM), allowing shareholders to participate remotely.
Agenda Highlights
The primary business of the AGM will be the consideration and adoption of the Company’s audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Alongside these, the reports from the Board of Directors and the Auditors will also be presented and considered.
Director Appointments and Remuneration
The agenda also includes several key resolutions concerning the company’s leadership and governance:
- Retirement of Shri Uday M. Patil: A resolution for the retirement by rotation of Shri Uday M. Patil, who is not offering himself for re-appointment as a Director.
- Appointment of Shri Nilesh Bhalchandra Patil: Resolutions propose the appointment of Shri Nilesh Bhalchandra Patil as a Director and as a Whole-time Director, subject to member approval.
- Re-appointment of Directors: Resolutions are included for the re-appointment of Shri Harshit Manilal Savla as Joint Managing Director, Shri Harit Pragji Shah as Whole-time Director, and Shri Hasmukh B. Dedhia and Shri Sandeep M. Joshi as Independent Directors for their second terms.
- Approval for Shri Prakash M. Patil’s Office/Place of Profit: A resolution seeks approval for Shri Prakash Moreshwar Patil to hold an office or place of profit in the Company as Management/Technical Consultant.
- Payment of Profit-Related Commission: A resolution proposes the payment of profit-related commission to Non-Executive Directors for a period of three years.
- Performance Stock Option Plan 2026 (PSOP 2026): The Company seeks approval for the introduction and implementation of an employee stock option plan.
- Ratification of Cost Auditors’ Remuneration: A resolution to ratify the remuneration of the cost auditors for the Financial Year 2026-27.
The Annual Report for FY 2025-26, along with the Notice of AGM, is available on the Company’s website at https://www.aartidrugs.com/reports-fillings-annual-reports.
Source: BSE
